U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2022 | Outperform → Perform | Oppenheimer | |
| 8/11/2022 | $6.00 → $2.40 | Buy → Neutral | B. Riley Securities |
| 3/10/2022 | $16.00 → $8.00 | Buy | B. Riley Securities |
| 3/8/2022 | $7.00 | Buy | ROTH Capital |
| 8/4/2021 | $11.00 → $12.00 | Buy | HC Wainwright & Co. |
3 - ChromaDex Corp. (0001386570) (Issuer)
4 - ChromaDex Corp. (0001386570) (Issuer)
3 - ChromaDex Corp. (0001386570) (Issuer)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
8-K - ChromaDex Corp. (0001386570) (Filer)
10-Q - ChromaDex Corp. (0001386570) (Filer)
8-K - ChromaDex Corp. (0001386570) (Filer)
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations. Effective October 21, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Mr. Fried commented, "We are very pleased to welcome Ozan to the ChromaDex team. His ambitious work ethic and impressive professional background will help us to embark on this critical next phase of develo
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective today, July 22, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Carlos Lopez is a distinguished legal professional and executive leader with expertise in the dietary supplements industry. Prior to joining ChromaDex, he served as the Vice President, General Counsel at The Vitamin Sh
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, 2024, based on the preliminary list of additions posted on Friday, May 24, 2024. Rob Fried, CEO of ChromaDex and Founder of Tru Niagen commented, "Joining the Russel
4 - ChromaDex Corp. (0001386570) (Issuer)
National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely accessible to wellness enthusiasts looking to enhance cellular health and extend their healthspan. Available in oral and IV
Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Thursday, October 31, 2024, at 4:30 p.m.
Oppenheimer downgraded ChromaDex from Outperform to Perform
B. Riley Securities downgraded ChromaDex from Buy to Neutral and set a new price target of $2.40 from $6.00 previously
B. Riley Securities reiterated coverage of ChromaDex with a rating of Buy and set a new price target of $8.00 from $16.00 previously
Results from the at-home test kit are available to HCPs and their patients through 1healthChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit*, now available exclusively through the company's healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex's NAD+-boosting HCP products, Tru Niagen® and Niagen+.
-SEC Filing
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV
Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Thursday, October 31, 2024, at 4:30 p.m.
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Wednesday, November 6, at 4:30 p.m. ET. Participants should call in